PR 101 eNEWSLETTER - SUBSCRIBE TODAY!
With simple tips and actionable advice, you'll be able to quickly and easily enhance the visibility of your product, service and brand.
“As President of a Las Vegas based boutique public relations firm working with limited staff and resources, I have found PR Newswire to be an extremely valuable tool in branding and marketing my clients. Representing small businesses and not-for-profit organizations with restrictive budgets (especially in the current economic climate), PR Newswire’s distribution services allows for what I note as the 4Es: the most efficient, effective and economical means of Exposure. Exposure that spans the nation and beyond! In addition to the traditional media pick-up, there are hundreds of TOP internet news rooms which post PR Newswire releases “word-for-word.” The internet news room postings have a two-fold effect: increasing the opportunity for media, businesses and consumers from across the globe to read the release, as well as enhancing the internet Search Engine Optimization (SEO) of the client and its product/service.”
Mary B. Vail, OSG
The Philanthropic Publicist
http://maryvailpublicist.com
Falcon Genomics, Inc. publishes validation data for Cancer BioChip System
Two publications highlight the Cancer BioChip System as a tool for functional genomic profiling of breast cancer
PITTSBURGH, Pa. Sept. 28, 2012 /PRNewswire-iReach/ -- The online journal PLOS ONE released a scientific report on the validation of Falcon Genomics' Cancer BioChip System (CBCS) as a tool for identifying inhibitors of breast cancer.
The PLOS ONE article titled: "Validation of the Cancer BioChip System as a 3D siRNA Screening Tool for Breast Cancer Targets" reported unique and selective suppression of 3D breast cancer tumor cell growth by targeting specific genes on the CBCS.
The Lead Investigator, Dr. Rula Abbud - Antaki, proposes that "…the CBCS is being developed as a in-vitro surrogate for identifying effective patient-specific therapies for breast cancer." The active agents tested in these papers consisted of silencing RNA (siRNA). Also known as small-interfering RNA, siRNA plays many roles, but its most notable is its ability to interfere with the expression of specific genes – such as those responsible for cancer. According to Abbud - Antaki, "silencing RNA is a very potent tool in the fight against cancer. It can be designed to target any and every gene in the human genome."
The CBCS was previously described in a June 15, 2012 article published by the journal Hormones and Cancer. This article defines the Cancer BioChip System as a "Functional Genomic Assay for Anchorage-Independent Three-Dimensional Breast Cancer Cell Growth." While there are other siRNA screening platforms, the CBCS is unique because it has higher clinical translatability through its patented 3-D culture technology. (US Patents 7,537,913 and 8,110,375).
Falcon Genomics, Inc. currently offers the CBCS as a service for high-throughput 3D siRNA screening. According to the authors, the CBCS will greatly reduce the attrition rate of cancer drug discovery leads. All drug screening tests use cell lines growing on flat surfaces, which resulted in many targets that never made it into the clinic. By testing the patient's own tumor cells in a 3D anchorage-independent in vitro setting, Falcon Genomics' CBCS can identify targets that have a high likelihood of clinical success, and may be overlooked by existing tests. Falcon Genomics, Inc. also envisions the CBCS as a personalized diagnostic test, whereby every patient tumor will be diagnosed based on its sensitivity to targeted therapy. Dr. Abbud - Antaki says, "This will greatly improve the success rate of breast cancer treatments."
About Falcon Genomics, Inc.
Falcon Genomics, Inc. is a privately held biotech Company whose mission is to provide genomic solutions for accurate diagnosis of cancer and discovery of targeted, patient-specific therapy. Falcon Genomics is currently marketing two services for cancer drug discovery, including a gene expression profiling service using the Affymetrix GeneAtlas System, and their proprietary Cancer BioChip System. Falcon Genomics' comprehensive genomic platform is geared towards translation of genomic breakthroughs into successful patient management and treatment. http://www.falcongenomics.com.
Media Contact: Rula Abbud-Antaki Falcon Genomics, Inc., 4128026236, rabbud@falcongenomics.com
News distributed by PR Newswire iReach: https://ireach.prnewswire.com
SOURCE Falcon Genomics, Inc.
